JP Morgan 31st Annual Healthcare Conference January 7-10th, 2013 San Francisco, CA. The Progenra Business Development Team will be attending and meeting with companies and investors interested in Progenra's business model and platform.
3rd Ubiquitin Research & Drug Discovery February 25-26th, 2013 Las Vegas, NV. Progenra's Dr. Mike Eddins will be attending this conference to contribute to the discssion around the ubiquitin pathway and meet with current and prospective partners.
BIO International Convention April 22-25th, 2013 Chicago, IL. The Progenra Business Development team will be attending and meeting with companies interested in partnering with Progenra on the company's internal programs or external discovery programs.
Ubiquitin Drug Discovery & Diagnostics Conference 2013 July 23-25th, 2013 Philadelphia, PA. Progenra is proud to be a major sponsor that hosts an exciting cast of ubiquitin-focused professionals from the academic, pharmaceutical, biotech and business communities.
FEBS Protein Quality Control & Ubiquitin Systems in Health &Disease November 14-16th, 2012 Kusadsdi, Turkey. Progenra scientits will be attending this conference to contribute to the discussions and meet with current and prospective partners.
Tech Transfer Summit North America October 22-23rd, 2012 Rockville, MD. Progenra's Sr. Director of Business Development, Marc Hixson, will be speaking on various roundtable topics such as tech transfer, partnering and licesning strategies for small biotechs.
Discovery on Target - Targeting the Ubiquitin Pathway October 1-2nd, 2012 Boston, MA. Progenra's Dr. Ben Nicholson will discuss the challenges of identifying small molecule inhibitors of both DUBs and E3 ligases and what the company has done to overcome them.
SBS 17th Annual Conference & Exhibition, March 27-31st, 2011. Dr. Craig Leach will detail Progenra's broad array of DUB and Ubiquitin E3 ligase assay platforms with particular emphasis on the identification of specific inhibitors.
American Chemical Society, Spring 2011 National Meeting and Exposition, March 27-31st, 2011. In a podium presentation, Dr. Ben Nicholson will present Progenra's progress towards identifying a clinical candidate USP7 inhibitor.
American Chemical Society, Spring 2011 National Meeting and Exposition, March 27-31st, 2011. In a podium presentation, Dr. Jian Wu will present Progenra's progress towards the development of new probes addressing the ubiquitin-proteasome pathway.
The American Society for Bone and Mineral Research March 21-22nd, 2011. Identification of inhibitors of the ubiquitin E3 ligase MuRF1 using a novel assay platform. Jeffrey Marblestone will discuss recent work on the creation of an E3 ligase platform that has detected several compounds now in pre-clinical development.
2010 2nd Cancer Targets & Therapeutics Conference, October 20-22, 2010. Dr. Craig Leach outlined Progenra's oncology programs with particular emphasis on USP7 inhibitors.
Ubiquitin Drug Discovery and Diagnostics 2010, August 24-25th, 2010. Discovery of Ubiquitin Isopeptidase Inhibitors. Dr. Ben Nicholson provided updates on Progenra's USP7 inhibitor discovery and early development programs, highlighting translational research and progress towards a clinical candidate.
Ubiquitin Drug Discovery and Diagnostics 2010, August 24-25th, 2010. Identification of E3 Ligase Inhibitors Using a Novel Assay. Dr. Michael Eddins presented data on Progenra's extensive portfolio of E3 ligase assay technologies including case studies with the novel muscle atrophy modulator, P13222.
5th Intracellular Proteolysis Meeting, May 4-7, 2010. The Role of Parkin in Neurodegeneration and Development of an E3 Ligase HTS Program. Senior Scientist, Jeffrey Marblestone presented the exciting progress on Progenra's proprietary ubiquitin E3 ligase screening platform.
Screening Europe 2010, February 11-12th, 2010. Discovery and Development of novel USP7 inhibitors. Dr. Craig Leach presented the latest progress on Progenra's DUB inhibitors.
51st ASH Annual Meeting and Exposition, December 5-8th, 2009. Deubiquitylating Enzyme USP-7, a Novel Therapeutic Target in Multiple Myeloma. Dr. Dharminder Chauhan (Dana Farber Cancer Institute, Boston, MA) will present exciting new data on the activity of Progenra's USP7 inhibitor, P5091 against cell based and in vivo models of multiple myeloma. Dr. Chauhan's oral presentation in the Myeloma - pathophysiology and preclinical studies excluding therapy: targeting intracellular proteolysis and the cell surface session, is scheduled for 3:30pm on Monday December 7th, 2009.
AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics, November 15-19th, 2009. Deubiquitylases as novel anti-cancer targets: Discovery and development of novel USP7 inhibitors. Dr. Benjamin Nicholson will present the latest progress on Progenra's USP7 inhibitor program.
2009 NCI SBIR Investor Forum, Progenra was invited to present its portfolio of products and technology in National Cancer Institute sponsored investment forum at Boston University on Nov 5th 2009. Dr Tauseef Butt, CEO of Progenra presented company product portfolio. The event was attended by pharma, biotech and major venture capital firms.
NCI Translational Science Meeting, November 5th-7th, 2009. Discovery and development of novel ubiquitin isopeptidase inhibitors. Dr. Craig Leach will present the latest progress on Progenra's DUB inhibitor programs including USP20 and USP7.
Ubiquitin Drug Discovery and Diagnostics 2009, October 13-14th, 2009. Discovery and development of the novel USP7 inhibitor, P5091. In a podium presentation, Dr. Nicholson will give an overview of Progenra's deubiquitylase discovery platform along with a presentation on recent data obtained with the P5091 series of USP7 inhibitors.
The Ubiquitin Workshop, October 12th, 2009. In podium presentations, Dr. Craig Leach discussed assays that are currently being used to explore the chemical space of deubiquitinases and Jeffrey Marblestone presented assays used to uncover selective modulators of E3 ligase activity. Both talks highlighted the technology that was developed and employed at Progenra to target enzymes in the ubiquitin-proteasome pathway.
June 26th, 2009, Progenra invited to speak at Drug Discovery Partnership Conference, October 28th-30th. Dr. Seth J. Goldenberg will discuss the advantages of startup - academic partnerships and how they can foster the drug development process from target validation through pre-clinical development.
Cold Spring Harbor- The Ubiquitin Family, April-21-25, 2009. Identification of inhibitors of ubiquitin E3 ligase activity using a novel assay platform. Jeff Marblestone and Dr. Michael Eddins will discuss their recent work on the creation of an E3 ligase platform that has detected several compounds now in pre-clinical development.
4th Intracellular proteolysis meeting, May 27-29, 2009. A Comprehensive Approach for Detecting Inhibitors of USP7 as a Therapeutic Target. Dr. Seth J Goldenberg will share exciting progress on a highly selective and potent USP7 compound discovered using Progenra' proprietary screening platform.
5th Annual Global Proteins Summit, June 1st-2nd. Protein Expression using a novel SUMO system. Senior Scientist Jeff Marblestone will discuss how Progenra expresses and purified several proteins of interest in the ubiquitin pathway using a robust SUMO-based protein expression system.
Target Discovery World Congress, August 4-5, 2009. Deubiquitylases as novel anti-cancer targets: Discovery and characterization of novel USP7 inhibitors. Dr. Suresh Kumar will talk about our progress on USP7 pipeline including selective and potent compounds discovered using Progenra' proprietary screening platform.
GTC Bio 6th Annual Cancer Drugs: Research and Development, Feb 19-20, 2009. Deubiquitylases as novel anti-cancer targets: Discovery and characterization of novel USP7 inhibitors. Dr. Craig A Leach discussed progress on our USP7 pipeline including selective and potent compounds discovered using Progenra' proprietary screening platform.
Keystone Symposia- The Many Faces of Ubiquitin, Jan 11-16, 2009. Discovery and Characterization of Novel USP7 inhibitors Dr. Benjamin Nicholson shared our progress on USP7 inhibitors that are rapidly moving through pre-clinical development.